Claritin Ripple Effects: Cardinal Manufacturing, Distribution Show OTC Impact
Executive Summary
The ripple effects from the OTC switch of Claritin will include a short-term margin challenge for Cardinal Health
You may also be interested in...
Claritin OTC Review: Broad Urticaria Label Would Better Reflect Actual Use
Urticaria indications for future antihistamine Rx-to-OTC switches should be broadened to include acute hives in order to reflect actual patient use, an FDA advisory committee recommended
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials